ODN 2088 Control (ODN 20958)

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.
ODN 2088 Control (ODN 20958) is a TLR7 antagonist. The sequence does not form G-tetrads.

Specifications for ODN 2088 Control (ODN 20958)

Overview

TLR7/8/9 antagonists consist of short single-stranded oligodeoxynucleotides. They can inhibit CpG ODN-mediated activation of TLR9 and/or activation of TLR7/8.
ODN 2088 Control (ODN 20958) is a TLR7 antagonist. The sequence does not form G-tetrads.

Detailed product information

Background information

TLR7, TLR8 and TLR9 are prominent members of the Toll-like-receptor (TLR) family recognizing pathogen-associated molecular patterns recognizing nucleic acids
3
. Activation of these TLRs can be inhibited by short single-stranded synthetical oligodeoxyribonucleotides (ODNs)
4,6
. Several classes of and motifs for inhibitory ODN have been identified
1,6,7
.

Applications

TLR7/8/9 Antagonists can be used to inhibit TLR7/8/9 mediated cellular responses, such as activation of immune cells, human PBMCs, murine splenocytes or isolated immune cells (e.g., B cells and pDCs).
TLR7/8/9 Antagonists can be used to inhibit signaling in TLR7/8/9-
expressing recombinant cell lines.
ODN 2088 Control (ODN 20958) is can be used as a sequence control for ODN 2088
1,2,4-7
and ODN 20959. ODN 2088 Control (ODN 20958) inhibits TLR7 mediated signalling but not TLR9 or TLR8 mediated signalling
1
.

References for ODN 2088 Control (ODN 20958)

Publications

  1. Hackstein H. et al. (2011) The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation. Cell. Immunol. 271: 401-412
  2. Jurk, M. et al. (2006) Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides. Eur. J. Immunol. 36: 1815-1826
  3. Kawai, T. and Akira, S. (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5): 373-384
  4. Krieg, A. M. et al. (1998) Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. U.S.A. 95: 12631-12636
  5. Lenert, P. et al. (2001) CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev. 11: 247-256
  6. Lenert, P. S. (2010) Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm 2010: 986596
  7. Stunz, L. L. et al. (2002) Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 32: 1212-1220

Seems like you are coming from USA!
Do you want to visit our website in your country?

Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.